Cyclosporin A in combination with HAART in primary HIV-1 infection

G. P. Rizzardi, M. Vaccarezza, B. Capiluppi, G. Tambussi, A. Lazzarin, G. Pantaleo

Research output: Contribution to journalArticlepeer-review


HAART is the cornerstone of HIV therapy, and has significantly reduced morbidity and mortality associated with HIV disease. The institution of HAART during the primary HIV-1 infection has a more profound influence on the ultimate pattern and rate of disease progression than therapy commenced later on. However, it also well demonstrated that HAART alone is not able to eradicate the virus, unless over a life-long period of time. There is therefore the need to develop alternative strategies aimed at modulating the immune responses in order to achieve the long-term control of HIV even once HAART is discontinued. Among immunomodulant agents, cyclosporin A in combination with HAART might play a role in the treatment of people with primary HIV-1 infection.

Original languageEnglish
Pages (from-to)79-81
Number of pages3
JournalJournal of Biological Regulators and Homeostatic Agents
Issue number1
Publication statusPublished - 2000


  • Cyclosporin A
  • HIV eradication
  • Immune-based strategies
  • Immunosuppression
  • Primary HIV-1 infection

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Physiology (medical)
  • Medicine (miscellaneous)
  • Physiology
  • Agricultural and Biological Sciences(all)


Dive into the research topics of 'Cyclosporin A in combination with HAART in primary HIV-1 infection'. Together they form a unique fingerprint.

Cite this